Key result
Dexrazoxane prevents anthracycline cardiotoxicity, sharpening the antitumor profile and therapeutic index.
Why the study?
Does dexrazoxane prevent anthracycline cardiotoxicity?
Does dexrazoxane prevent anthracycline cardiotoxicity?
Dexrazoxane may prevent anthracycline-induced cardiotoxicity, potentially improving the therapeutic index of anthracyclines.
Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.2.332 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8636740 Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index. K HellmannxK HellmannSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.2.332 PDF "Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index.." Journal of Clinical Oncology, 14(2), pp. 332–333© 1996 by American Society of Clinical Oncology
No takes yet. Share an insight, caveat, or question.
K. Hellmann (1996) conducted an editorial in Anthracycline cardiotoxicity. Dexrazoxane was evaluated. Dexrazoxane prevents anthracycline cardiotoxicity, sharpening the antitumor profile and therapeutic index.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: